Research Portfolio

Funding Opportunities

Join our Mailing List
Join our mailing list to be notified of new funding opportunities.

Your Email

To receive information about funding opportunities, events, and program updates.

Gene-modified Stromal Cell Therapy for Lung Cancer

Institution: University of California, Los Angeles
Investigator(s): Minu Srivastava, Ph.D.
Award Cycle: 2011 (Cycle 20) Grant #: 20FT-0083 Award: $60,498
Subject Area: Cancer
Award Type: Postdoctoral Fellowship Awards

Initial Award Abstract
Lung cancer is the leading cause of cancer-related deaths in the United States. Lung cancer accounted for a total of 159,390 estimated deaths in 2009 in the United States. Approximately, 219,440 new cases occur every year in the United States and worldwide, more than 1.1 million people die from lung cancer annually. Epidemiological studies have shown that there is a strong correlation between tobacco smoking and lung cancer. Approximately 80-85% of all lung cancers occur in the current or former cigarette smokers. At present in the United Stated, there are currently fifty million smokers and fifty million former smokers. Hence, approximately one third of US population is at high risk of developing lung cancer. Surgery, chemotherapy and multimodal treatments are currently available for the treatment of lung cancer; however, 50% of patients experience cancer recurrence after surgery and less than 25% respond to chemotherapy. Despite improvements in the detection and treatment of lung cancer in the past two decades, the long term survival for lung cancer patients remains low with only 15% surviving for 5 years following diagnosis and no patients are being completely cured. Therefore, new approaches for the treatment of lung cancer are urgently needed. One such approach would be to develop immune therapy for lung cancer. Strategies that activate the immune system to react against tumors can be integrated with existing forms of therapy for optimal responses toward this devastating disease. In this proposal we will study how genetically engineered stromal cells expressing a protein CCL21 activate the immune cells of our body to fight lung cancer. We will also study the effect of this therapy on cells that impair our immune system to fight lung cancer. We will use the findings from this study to improve the therapy by using combined approaches that will target the cells that impair this therapy.


Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer
Periodical: PLOS One Index Medicus:
Authors: Minu K Srivastava, Li Zhu, Marni Harris-White, Upendra Kar, Min Huang, Ming. F. Johnson, J ART
Yr: Vol: Nbr: Abs: Pg:

Myeloid Cell Mediated Programming of the Tumor Microenvironment in the book Tumor Microenvironment and Myelomonocytic Cells
Periodical: Immunotherapy Index Medicus:
Authors: Minu K. Srivastava, Marni Harris-White, Li Zhu, Steven Dubinett, Sherven Sharma ART
Yr: 2012 Vol: 4 Nbr: 3 Abs: Pg: 291-304

Novel CCL21-Vault Nanocapsule Intratumoral Delivery Inhibits Lung Cancer Growth_x000D_
Periodical: PLOS One Index Medicus:
Authors: Upendra K Kar, Minu K Srivastava, ├ůsa Andersson, Felicita Baratelli, Min Huang, Valerie A ART
Yr: Vol: Nbr: Abs: Pg:

Targeting MDSCs enhance therapeutic vaccination responses against lung cancer_x000D_
Periodical: OncoImmunology Index Medicus:
Authors: Minu K Srivastava, Steven Dubinett, Sherven Sharma ART
Yr: 2012 Vol: Nbr: Abs: Pg:

Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer
Periodical: ImmunoTargets and Therapy Index Medicus:
Authors: Srivastava MK, Zhu L, Harris-White M, Huang M, St John M, Lee JM, Salgia R, Cameron RB, St ART
Yr: 2012 Vol: 2012 Nbr: 1 Abs: Pg: 7-12